WO2009066462A1 - 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン - Google Patents

細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン Download PDF

Info

Publication number
WO2009066462A1
WO2009066462A1 PCT/JP2008/003419 JP2008003419W WO2009066462A1 WO 2009066462 A1 WO2009066462 A1 WO 2009066462A1 JP 2008003419 W JP2008003419 W JP 2008003419W WO 2009066462 A1 WO2009066462 A1 WO 2009066462A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cytotoxic
inducer
vaccine
induction
Prior art date
Application number
PCT/JP2008/003419
Other languages
English (en)
French (fr)
Inventor
Tomoya Miyakawa
Keiko Udaka
Original Assignee
Nec Corporation
Kochi University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nec Corporation, Kochi University filed Critical Nec Corporation
Priority to JP2009542482A priority Critical patent/JPWO2009066462A1/ja
Priority to US12/743,733 priority patent/US20100255020A1/en
Priority to EP08852946A priority patent/EP2216041A4/en
Publication of WO2009066462A1 publication Critical patent/WO2009066462A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　配列番号１、２および３よりなる群より選ばれる１種以上のアミノ酸配列を含み、かつ、８以上１１以下のアミノ酸残基からなるペプチド、またはその前駆体由来のペプチドを、細胞傷害性Ｔ細胞の標的となる細胞の表面のＨＬＡ分子に結合させることを含むことを特徴とする細胞傷害性Ｔ細胞の誘導方法が提供される。  
PCT/JP2008/003419 2007-11-20 2008-11-20 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン WO2009066462A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009542482A JPWO2009066462A1 (ja) 2007-11-20 2008-11-20 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
US12/743,733 US20100255020A1 (en) 2007-11-20 2008-11-20 Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
EP08852946A EP2216041A4 (en) 2007-11-20 2008-11-20 METHOD FOR INDUCING CYTOTOXIC LYMPHOCYTE T, CYTOTOXIC LYMPHOCYTE T INDUCER, AND PHARMACEUTICAL COMPOSITION AND VACCINE COMPRISING EACH INDUCER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007301000 2007-11-20
JP2007-301000 2007-11-20

Publications (1)

Publication Number Publication Date
WO2009066462A1 true WO2009066462A1 (ja) 2009-05-28

Family

ID=40667295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003419 WO2009066462A1 (ja) 2007-11-20 2008-11-20 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン

Country Status (4)

Country Link
US (1) US20100255020A1 (ja)
EP (1) EP2216041A4 (ja)
JP (1) JPWO2009066462A1 (ja)
WO (1) WO2009066462A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007266A1 (ja) * 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
JP5885885B2 (ja) * 2013-03-29 2016-03-16 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
WO2018219299A1 (en) * 2017-05-31 2018-12-06 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013089252A1 (ja) * 2011-12-14 2013-06-20 国立大学法人 高知大学 ヘルパーｔ細胞誘導性ポリペプチドの改変
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
CN110491450B (zh) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 肿瘤新生抗原预测平台及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11316754A (ja) 1998-05-06 1999-11-16 Nec Corp 実験計画法及び実験計画プログラムを記録した記録媒体
JP2002525099A (ja) * 1998-09-30 2002-08-13 コリクサ コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
WO2006004182A1 (ja) 2004-07-07 2006-01-12 Nec Corporation 配列予測システム
WO2007120673A2 (en) * 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) * 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
JP4621142B2 (ja) * 2003-11-05 2011-01-26 株式会社癌免疫研究所 Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
ES2402184T5 (es) * 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos
EP2186896B1 (en) * 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
WO2006030770A1 (ja) * 2004-09-17 2006-03-23 Nec Corporation Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
CN101646455A (zh) * 2007-02-07 2010-02-10 财团法人阪大微生物病研究会 用于癌症的治疗剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11316754A (ja) 1998-05-06 1999-11-16 Nec Corp 実験計画法及び実験計画プログラムを記録した記録媒体
JP2002525099A (ja) * 1998-09-30 2002-08-13 コリクサ コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
WO2006004182A1 (ja) 2004-07-07 2006-01-12 Nec Corporation 配列予測システム
WO2007120673A2 (en) * 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WTl-specific cytotoxic T lymphocytes", CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 7402 - 7412
A. TSUBOI ET AL.: "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues", CANCER IMMUNOL IMMUNOTHER., vol. 51, 2002, pages 614 - 620
ALTMAN, JD; MOSS, PA.; GOULDER, PJ; BAROUCH, DH; MCHEYZER-WILLIAMS; MG, BELL, JI; MCMICHAEL, AJ; DAVIS, MM.: "Phenotypic analysis of antigen-specific T lymphocytes", SCIENCE, vol. 274, 1998, pages 94 - 96
GAO, L.; BELLANTUONO, I.; ELSASSER, A.; MARLEY, S.B.; GORDON, M.Y.; GOLDMAN, J.M.; STAUSS, H.J.: "Selective elimination of leukemic CD34 + progenitor cells by cytotoxic T lymphocytes specific for WT1.", BLOOD, vol. 95, 2000, pages 2198 - 2203
H. OHMINAMI; M. YASUKAWA; S. FUJITA: "HLA class I-restricted lysis of leukemia cells by a CD8 + cytotoxic T-lymphocyte clone specific for WT1 peptide", BLOOD, vol. 95, 2000, pages 286 - 293
JAN KLEIN; FELIPE FIGUEROA, CRC CRITICAL REVIEWS IN IMMUNOLOGY, vol. 6, no. 4, 1986, pages 295 - 386
MASHIBA ET AL., IMMUNOGENETICS, vol. 59, 2007, pages 197 - 209
MENKE, A.L.; VAN DER EB, A.J.; JOCHEMSEN, A.G.: "The Wilms' tumor 1 gene: oncogene or tumor suppressor gene?", INTERNATIONAL REVIEW OF CYTOLOGY, vol. 181, 1998, pages 151 - 212
MOSOLITS, S.; ULLENHAG, G.; MELLSTEDT, H.: "Therapeutic vaccination in patients with gastrointestinal malignancies. A review of Immunological and clinical results", ANN ONCOL, vol. 16, 2005, pages 847 - 862
NAGORSEN, D.; E. THIEL.: "Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer", CLIN CANCER RES, vol. 12, 2006, pages 3064 - 3069
NAKATSUKA, S.; OJI, Y.; HORIUCHI, T. ET AL.: "Immunohistochemical detection of WT1 protein in a variety of cancer cells.", MODERN PATHOLOGY, vol. 19, 2006, pages 804 - 814
ROSENBERG, S.A.; YANG, J.C.; SCHWARTZENTRUBER, D.J.; HWU, P.; MARINCOLA, F.M.; TOPALIAN, S.L.; RESTIFO, N.P.; DUDLEY, M.E.; SCHWAR: "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", NAT MED, vol. 10, 2004, pages 909 - 915
See also references of EP2216041A4
SLINGLUFF, C. L.; PETRONI, G.R.; YAMSHCHIKOV, G.V.; BARND, D.L.; EASTHAM, S.; GALAVOTTI, H.; PATTERSON, J.W.; DEACON, D.H.; HIBBIT: "Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells", J CLIN ONCOL, vol. 21, 2003, pages 4016 - 4026
THERESSE, P. ET AL., J NATL CANCER INST., vol. 92, 2000, pages 205 - 216
UDAKA ET AL., IMMUNOGENETICS, vol. 51, 2000, pages 816 - 828
Y. OKA; O.A. ELISSEEVA; A. TSUBOI; H. OGAWA; H. TAMAKI; H. LI; Y. OJI; E.H. KIM; T. SOMA; M. ASADA: "Human cytotoxic T-lymphocyte response specific for peptides of the wild-type Wilms' tumor gene (WT1) product.", IMMUNOGENETICS, vol. 51, 2000, pages 99 - 107

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007266A1 (ja) * 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
JPWO2014007266A1 (ja) * 2012-07-02 2016-06-02 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
JP5885885B2 (ja) * 2013-03-29 2016-03-16 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
JPWO2014157692A1 (ja) * 2013-03-29 2017-02-16 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
WO2018219299A1 (en) * 2017-05-31 2018-12-06 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy
KR20200016873A (ko) * 2017-05-31 2020-02-17 칼스젠 테라퓨틱스 씨오., 엘티디. 세포 면역 요법을 위한 조성물 및 방법
KR102412805B1 (ko) 2017-05-31 2022-06-27 크라제 메디컬 씨오 리미티드 세포 면역 요법을 위한 조성물 및 방법
US11419895B2 (en) 2017-05-31 2022-08-23 Crage Medical Co., Limited Compositions and methods of cellular immunotherapy

Also Published As

Publication number Publication date
EP2216041A4 (en) 2012-10-24
JPWO2009066462A1 (ja) 2011-04-07
US20100255020A1 (en) 2010-10-07
EP2216041A1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
WO2009066462A1 (ja) 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
EP2455462A3 (en) Lipase variants for pharmaceutical use
NZ710626A (en) Pcsk9 vaccine
EP2594582A3 (en) Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens
RU2016146198A (ru) Терапевтические dll4-связывающие белки
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
NZ598356A (en) Antigenic tau peptides and uses thereof
MX2008009493A (es) Peptido novedoso y uso del mismo.
RS54204B1 (en) NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
NZ590010A (en) Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
MX2009007261A (es) Vacuna de peptido foxp3.
WO2008113536A8 (en) Neurotrophic peptides
ZA200802440B (en) Compositions and methods for diagnosing and treating an inflammation
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2009072555A1 (ja) 癌ワクチン
MX2010005816A (es) Epítopos de péptido de stat3.
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08852946

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009542482

Country of ref document: JP

Ref document number: 12743733

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008852946

Country of ref document: EP